[Skip to content]

Royal Brompton & Harefield NHS Foundation Trust
Our research
Search our Site

UBIOPRED study completes recruitment 

The U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) project is a cross-sectional and longitudinal clinical study. Researchers are looking to learn more about the different types of asthma to ensure better diagnosis and treatment for each person by using information and data obtained from samples from both adults and children

UBIOPRED is a European-based public-private partnership consisting of universities, hospitals, pharmaceutical companies, small-medium enterprises and patient associations and is funded by the EU Innovation Medicines Initiative.

The aims of the project are to characterise patients with severe asthma and compare these characteristics with those of mild to moderate asthmatics and healthy controls, to enable the linking of molecular targets for drug intervention with the pathophysiology of severe asthma, and finally to integrate all the data collected from severe asthma patients so that phenotype fingerprints and ultimately a ‘handprint’ of severe asthma can be developed.

UBIOPRED has completed recruitment together with the one year longitudinal visit in July 2014, with 1,029 research participants across both adult and paediatric cohorts. The severe asthma research team within the NIHR Royal Brompton Respiratory BRU, led by Professor Fan Chung, contributed 134 adult and 81 paediatric participants to the UBIOPRED European Consortium; 52 of the adult participants gave consent for undertaking a fiberoptic bronchoscopy and 47 a high resolution computed tomography of the lungs.

Blood, urine, exhaled breath and airway samples from adult and paediatric participants were collected and stored in the CIMGR Biobank in Manchester. Measurements from these samples have been mostly completed. 

All the data collected including information obtained from participants and from the sample analysis including the multiple parameters of clinical, functional, cellular, molecular and patient-reported outcomes are being integrated using a systems biology approach to develop phenotype fingerprints and ultimately ‘handprints’ of severe asthma. This work is being undertaken by a team of bioinformaticians, computer experts, biologists and medical doctors within the UBIOPRED Consortium. The analysis will be completed by mid-2015.  

Preliminary results from this study were presented at this year’s European Respiratory Society Congress in Munich. More information regarding the UBIOPRED project and the abstracts submitted to the Congress can be found here

August 2014

Back to BRU news